Compare WIX & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WIX | FOLD |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.5B |
| IPO Year | 2013 | 2006 |
| Metric | WIX | FOLD |
|---|---|---|
| Price | $47.96 | $14.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 9 |
| Target Price | ★ $134.67 | $27.25 |
| AVG Volume (30 Days) | 2.5M | ★ 2.5M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.80 | $20.50 |
| Revenue Next Year | $13.21 | $18.59 |
| P/E Ratio | $28.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.90 | $5.66 |
| 52 Week High | $190.92 | $14.50 |
| Indicator | WIX | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 33.52 | 74.18 |
| Support Level | N/A | $14.21 |
| Resistance Level | $93.82 | N/A |
| Average True Range (ATR) | 3.86 | 0.02 |
| MACD | -0.17 | -0.00 |
| Stochastic Oscillator | 7.83 | 100.00 |
Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves, or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years it has invested heavily and introduced its Wix Studio offering for partners, who are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.